Science Explorer Interactive view Map

Cancer Genomics and Diagnostics

Cancer Genomics and Diagnostics is a research topic within Cancer Research. Science Explorer counts 60k research works in it since 1950. 18.3% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the genomic landscape of cancer, mutational signatures, intratumor heterogeneity, liquid biopsies, somatic mutations, tumor evolution, cell-free DNA, genomic instability, targeted therapy, and clonal evolution in various cancer types.

  • Cancer Genomics
  • Mutational Signatures
  • Intratumor Heterogeneity
  • Liquid Biopsies
  • Somatic Mutations
  • Tumor Evolution
  • Cell-Free DNA
  • Genomic Instability
  • Targeted Therapy
  • Clonal Evolution
Research works
60k
fractional, since 1950
In the world top 10%
11k
per year above
Top-10% rate
18.3%
share of its works in the world top 10%
Growth, 2013–17 → 2018–22
+53%
the tick is no change

Which countries lead Cancer Genomics and Diagnostics research?

By volume, the United States and China publish the most (5.4k and 2.3k works in 2022–2025).

By volume, 2022–2025

  1. 1 United States 5.4k works
  2. 2 China 2.3k works
  3. 3 United Kingdom 692 works
  4. 4 Germany 664 works
  5. 5 Italy 631 works
  6. 6 Japan 622 works
  7. 7 India 521 works
  8. 8 France 458 works
  9. 9 Canada 421 works
  10. 10 Spain 405 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 44.7%China: 18.8%United Kingdom: 5.7%Germany: 5.5%6 others listed: 25.3%45%largest
United States5,406 · 44.7%China2,277 · 18.8%United Kingdom692 · 5.7%Germany664 · 5.5%6 others listed3,057 · 25.3%

Shares of the rows listed above, not of the whole node.

Which institutions lead Cancer Genomics and Diagnostics research?

By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Cancer Genomics and Diagnostics research, followed by Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute.

Who are the leading researchers in Cancer Genomics and Diagnostics?

The most-cited researchers publishing on Cancer Genomics and Diagnostics include Robert Tibshirani, Stacey Gabriel and Bert Vogelstein.

  1. 1 Robert Tibshirani United States 13k citations
  2. 2 Stacey Gabriel United States 7.8k citations
  3. 3 Bert Vogelstein United States 7.1k citations
  4. 4 Todd R. Golub United States 6.8k citations
  5. 5 Benjamin L. Ebert United States 6.7k citations
  6. 6 Gad Getz United States 6.2k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

Where is Cancer Genomics and Diagnostics research done?

The largest centres of Cancer Genomics and Diagnostics research in 2022–2025 are New York (United States), Beijing (China), Houston (United States) and Shanghai (China). Among places with at least 20 works in it, it is an unusually large share of all research in Cambridge, San Carlos and Redwood City.

Largest cities, 2022–2025

  1. 1 New York United States 397 works
  2. 2 Beijing China 357 works
  3. 3 Houston United States 285 works
  4. 4 Shanghai China 277 works
  5. 5 London United Kingdom 251 works
  6. 6 Boston United States 245 works
  7. 7 Seoul South Korea 230 works
  8. 8 Guangzhou China 220 works
  9. 9 Tokyo Japan 179 works
  10. 10 Toronto Canada 175 works

Where it is the local speciality

  1. Cambridge24.3 works124×
  2. San CarlosUS · 22.1 works96×
  3. Redwood CityUS · 44.7 works44×
← less than its size predictsmore →

Location quotient: how much more of its research is in Cancer Genomics and Diagnostics than the world average.

See Cancer Genomics and Diagnostics on the map

Where is the best place to study Cancer Genomics and Diagnostics?

Among universities, judged by research, Oncode Institute, Institute of Cancer Research and Shanghai Medical College of Fudan University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 25.23%fractional works in this node (log) →share in the world top 10% →Oncode Institute: 14, 36.0%Institute of Cancer Research: 18, 23.5%Shanghai Medical College of Fudan University: 11, 30.7%Chinese Academy of Medical Sciences & Peking Union Medical College: 76, 18.7%Icahn School of Medicine at Mount Sinai: 41, 20.0%Weill Cornell Medicine: 22, 18.7%Heidelberg University: 37, 26.9%Chinese University of Hong Kong: 20, 35.9%Harbin Medical University: 24, 18.2%Medical University of Graz: 13, 23.7%Oncode InstituteShanghai Medical Col…Institute of Cancer …Chinese Academy of M…
above the meannear itbelow it

One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.

#UniversityScoreTop 10%SpecialisationWorksGrowth
1 Oncode InstituteNetherlands 74.836.0%32.2×14 +206.5%
2 Institute of Cancer ResearchUnited Kingdom 58.423.5%38.8×18 +75.0%
3 Shanghai Medical College of Fudan UniversityChina 58.330.7%9.7×11 +99.7%
4 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 56.718.7%5.4×76 +249.9%
5 Icahn School of Medicine at Mount SinaiUnited States 55.820.0%5.8×41 +278.2%
6 Weill Cornell MedicineUnited States 53.618.7%11.7×22
7 Heidelberg UniversityGermany 52.626.9%4.8×37 +99.9%
8 Chinese University of Hong KongHong Kong 51.935.9%2.0×20 +115.9%
9 Harbin Medical UniversityChina 51.718.2%8.0×24 +148.0%
10 Medical University of GrazAustria 51.123.7%7.4×13 +103.2%

Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.

Is Cancer Genomics and Diagnostics research growing?

Output in 2018–2022 was 53% higher than in 2013–2017, peaking in 2023. The fastest-growing topics are Cancer Genomics and Diagnostics.

19801990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.